These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2127353)

  • 1. [Thrombolysis in acute myocardial infarction. Streptokinase or r-TPA?].
    Silva LA; Ribeiro E; Carneiro RC; Kaissar S; Reis Filho A; Torossian SP; Tavares JR; Buffolo E; Amino JG; Duprat Filho R
    Arq Bras Cardiol; 1990 Jul; 55(1):13-7. PubMed ID: 2127353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early reperfusion and late clinical outcomes in patients presenting with acute myocardial infarction randomly assigned to primary percutaneous coronary intervention or streptokinase.
    Berrocal DH; Cohen MG; Spinetta AD; Ben MG; Rojas Matas CA; Gabay JM; Magni JM; Nogareda G; Oberti P; Von Schulz C; Doval H; Bazzino OO; Cagide A; Oliveri R; Grinfeld LR
    Am Heart J; 2003 Dec; 146(6):E22. PubMed ID: 14661011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial of China-made recombinant streptokinase in acute myocardial infarction. Collaborative Study Group on Thrombolysis with China-made recombinant streptokinase.
    Chin Med J (Engl); 1997 Jan; 110(1):50-2. PubMed ID: 9594322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Endovenous thrombolysis in acute myocardial infarct. The experience in a community hospital. An analysis of 120 patients].
    Jorge Sdo C
    Arq Bras Cardiol; 1992 Jul; 59(1):23-30. PubMed ID: 1341143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A randomized study of streptokinase and recombinant tissue plasminogen activator, with and without heparin, in patients with acute myocardial infarction. The results of GISSI-2/International tPA/SK Mortality Trial].
    Steffensen R; Sandøe E
    Ugeskr Laeger; 1991 Oct; 153(41):2880-3. PubMed ID: 1949301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
    Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
    Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
    Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
    Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Platelet activation in the early phases of acute myocardial infarction].
    Salvioni A; Giraldi F; Assanelli E; Lauri G; Grazi M; Pardea S; Marenzi G
    Cardiologia; 1998 Aug; 43(8):825-32. PubMed ID: 9808873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of late potentials after myocardial infarction treated with systemic thrombolysis or primary percutaneous transluminal coronary angioplasty.
    Bruna C; Rossetti G; Vado A; Racca E; Steffenino G; Dellavalle A; Ribichini F; Ferrero V; Menardi E; Uslenghi E
    G Ital Cardiol; 1998 Jan; 28(1):3-11. PubMed ID: 9493040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated infusion of streptokinase in acute myocardial infarction results in better TIMI flow grade in infarct-related artery.
    Dwivedi SK; Saran RK; Narain VS; Bansal S; Gupta R; Puri VK
    Indian Heart J; 2000; 52(1):40-4. PubMed ID: 10820932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
    Tsui W; Pierre K; Massel D
    Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypotension in acute myocardial infarction patients given streptokinase.
    Lateef F; Anantharaman V
    Singapore Med J; 2000 Apr; 41(4):172-6. PubMed ID: 11063182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of recombinant tissue-type plasminogen activator thrombolysis and primary coronary stenting after acute myocardial infarction.
    Chen B; Wang W; Zhao H; Hu D; Xu C; Zhao M; Lu M; Liu J; Wu C
    Chin Med J (Engl); 2003 Jan; 116(1):142-4. PubMed ID: 12667408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.
    Steg PG; Laperche T; Golmard JL; Juliard JM; Benamer H; Himbert D; Aubry P
    J Am Coll Cardiol; 1998 Mar; 31(4):776-9. PubMed ID: 9525545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [R-R variability in acute anterior infarct after thrombolytic therapy].
    Boghossian SH; Maia IG; Costa Filho R; Alves PA
    Arq Bras Cardiol; 1992 Nov; 59(5):365-8. PubMed ID: 1340735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.
    Lancet; 1990 Jul; 336(8707):65-71. PubMed ID: 1975321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In-hospital survival predictors in infarction patients undergoing fibrinolytic therapy].
    Nicolau JC; Pinto MA; Nogueira PR; Lorga AM; Jacob JL; Garzon SA
    Arq Bras Cardiol; 1993 Sep; 61(3):143-8. PubMed ID: 8110042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Kentucky Acute Myocardial Infarction Trial (KAMIT) Group.
    Grines CL; Nissen SE; Booth DC; Gurley JC; Chelliah N; Wolf R; Blankenship J; Branco MC; Bennett K; DeMaria AN
    Circulation; 1991 Aug; 84(2):540-9. PubMed ID: 1907228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
    Fung AY; Lorch G; Cambier PA; Hansen D; Titus BG; Martin JS; Lee JJ; Every NR; Hallstrom AP; Stock-Novack D; Scherer J; Weaver WD
    Am Heart J; 1999 Oct; 138(4 Pt 1):696-704. PubMed ID: 10502216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.